Professor, Psychiatry, Virginia Commonwealth University, Medical College of Virginia School of Medicine

Psychiatry

Dr. Susan G. Kornstein is an expert in the field of Psychiatry. She researched medicine at Warren Alpert Medical School of Brown University. Susan Kornstein has written publications. She has 98 publications published with PubMed. The lastest paper is: 'The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine.'

Publications

---

• An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of Major depressive disorder.
• The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies.
• Desvenlafaxine for the treatment of Major depressive disorder.
• Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with majo...
• Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent Major depressive disorder treated with venlafaxine extended re...
• Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder.
• Do Menopausal Status and Use of Hormone Therapy Affect Antidepressant Treatment Response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STA...
• Assessment of depressive symptoms and functional outcomes in patients with Major depressive disorder treated with duloxetine versus placebo: primary outcomes from two ...
• Assessing anxious features in depressed outpatients.
• Determination of premenstrual symptom exacerbations.
• Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for Major depressive disorder...
• Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study.
• Focus on Women's Mental Health.
• A genomewide association study of citalopram response in Major depressive disorder-a psychometric approach.
• Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with Major depressive disorder.
• The influence of menopause status and postmenopausal use of hormone therapy on presentation of Major depression in women.
• Desvenlafaxine and escitalopram for the treatment of postmenopausal women with Major depressive disorder.
• Preface: Advances in women's mental health.
• Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with Major depressive disorder.
• Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report.
• Interpreting Premenstrual Symptoms Impact Survey scores using outcomes in health-related quality of life and sexual drive impact.
• Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with Major depressive disorder: a pooled analysis of 9 d...
• Escitalopram versus SNRI antidepressants in the acute treatment of Major depressive disorder: integrative analysis of four double-blind, randomized clinical trials.
• An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of Major depressive disorder.
• An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with Major depressive disorder.
• Assessing Rates and Predictors of Tachyphylaxis During the Prevention of Recurrent Episodes of Depression With Venlafaxine ER for Two Years (PREVENT) Study.
• Analysis of depressive symptoms in patients with Major depressive disorder treated with desvenlafaxine or placebo.
• Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptoms.
• Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with Major depression.
• A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of Major depressive disorder after initial duloxetine therapy.
• Development and validation of the Premenstrual Symptoms Impact Survey (PMSIS): a disease-specific quality of life assessment tool.
• Implications of Pain in Generalized Anxiety Disorder: Efficacy of Duloxetine.
• The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.
• A comparison of initial duloxetine dosing strategies in patients with Major depressive disorder.
• The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
• Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study.
• Acute worsening of chronic depression during a double-blind, randomized clinical trial of antidepressant efficacy: differences by sex and menopausal status.
• Duloxetine in Practice-Based Clinical Settings: Assessing Effects on the Emotional and Physical Symptoms of Depression in an Open-Label, Multicenter Study.
• Beyond remission: rationale and design of the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study.
• Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.
• Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies.
• Duloxetine efficacy for Major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.
• Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of SSRIs.
• Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions.
• Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not.
• Self-reported Depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients.
• Mental symptoms and Disorders during pregnancy.
• A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction.
• Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression.
• Gender differences in depression and response to antidepressant treatment.
• Chronic depression and comorbid personality Disorders: response to sertraline versus imipramine.
• Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.
• Sexual function and satisfaction in the treatment of chronic Major depression with nefazodone, psychotherapy, and their combination.
• Chronic depression in women.
• Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of Major depression.
• Symptomatic and syndromal anxiety in chronic forms of Major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combinat...
• Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression.
• Does psychosocial functioning improve independent of Depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination.
• Remission as the critical outcome of depression treatment.
• Gender-specific differences in depression and treatment response.
• The evaluation and management of depression in women across the life span.
• Clinical features of treatment-resistant depression.
• Sertraline versus imipramine to prevent relapse in chronic depression.
• Comparison of DSM-III-R chronic Major depression and Major depression superimposed on dysthymia (double depression): validity of the distinction.
• Gender differences in treatment response to sertraline versus imipramine in chronic depression.
• Gender differences in chronic Major and double depression.
• Enhancing pharmacologic effects in the treatment of depression in women.
• Lost human capital from early-onset chronic depression.
• The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine.
• The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine.
• Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial.
• Women in medicine: shaping the future.
• Gender differences in depression: implications for treatment.
• Menstrual migraines: etiology, treatment, and relationship to premenstrual syndrome.
• Gender differences in presentation of chronic Major depression.
• Differential diagnosis of chronic Depressive disorders.
• Tight binding inhibitors--IX. Kinetic parameters of dihydrofolate reductase inhibited by methotrexate, an example of equilibrium study.
• Psychiatric complications of closed head trauma.
• The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chron...
• Suicide risk management for the sequenced treatment alternatives to relieve depression study: applied NIMH guidelines.
• Gender differences in depression: findings from the STAR*D study.
• Self-reported premenstrual exacerbation of depressive symptoms in patients seeking treatment for Major depression.
• Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of Major depression and childhood trauma.
• Duloxetine in the treatment of Major depressive disorder: comparisons of safety and tolerability in male and female patients.
• Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in Major depressive disorder: gender-age interactions.
• Duloxetine as an SNRI treatment for generalized anxiety Disorder: results from a placebo and active-controlled trial.
• Influences of hormone-based contraception on depressive symptoms in premenopausal women with Major depression.
• Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with Major depressive disorder.
• Long-term tolerability and effectiveness of duloxetine in the treatment of Major depressive disorder.
• Burden of premenstrual dysphoric Disorder on health-related quality of life.
• What predicts attrition in second step medication treatments for depression?: a STAR*D Report.
• Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study.
• Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study.
• Early improvement during duloxetine treatment of generalized anxiety Disorder predicts response and remission at endpoint.
• Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent Major depression: a secondary ana...
• Sex differences in response to citalopram: a STAR*D report.
• Why do faculty leave? Reasons for attrition of women and minority faculty from a medical school: four-year results.

Schools

---

• Brown University Alpert Medical School

• Med College Va

Procedures Preformed

---

• Psychotherapy and Psychophysiological Therapy (incl. Biofeedback)

Conditions Treated

---

• Major Depressive Disorder

Doctors Specialties

---

• Psychiatry

Accepted Insurances

---

Education

---

• Virginia Commonwealth University Health System
• Warren Alpert Medical School of Brown University

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Eli J. Zaller, MD This Doctor is OpenDoctor Recommended.
	Dr. Wesley E. McEntire, MD This Doctor is OpenDoctor Recommended.
	Dr. Joel B. Moran, MD This Doctor is OpenDoctor Recommended.
	Dr. Elbert F. Sholar, MD This Doctor is OpenDoctor Recommended.
	Dr. Ahmed Sherif S. Abdel Meguid, MD This Doctor is OpenDoctor Recommended.
	Dr. Shana Berger, MD
	Dr. Gerald A. Demasters, MD This Doctor is OpenDoctor Recommended.
	Dr. Bandhan Chakraborty, MD
	Dr. Jaclyn N. Crawford, DO
	Dr. Pearl J. Bader, MD This Doctor is OpenDoctor Recommended.
	Dr. Akm Sulaman, MD
	Dr. Dana M. Soper, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog